Dr. Raje Compares Data for Triplet Regimens in Myeloma

Noopur Raje, MD
Published: Wednesday, Apr 17, 2019



Noopur Raje, MD, professor of medicine at Harvard Medical School and director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discusses data for the standard triplet regimens in the treatment of patients with relapsed/refractory multiple myeloma.

The data are promising with regard to the 3-drug combination of carfilzomib (Kyprolis), pomalidomide (Pomalyst), and dexamethasone, Raje says. Response rates are between 60% and 70%, with durations of response of approximately 8 or 9 months.

Moreover, combinations with daratumumab (Darzalex) have also been impressive. The triplet of daratumumab, dexamethasone, and pomalidomide also yields responses in approximately 60% of patients, with durations of response between 8 to 10 months. However, the field is shifting toward the use of quadruplets in this setting, with the goal of achieving minimal residual disease negativity and, ultimately, higher cure rates. Data show that treatment with 4-drug regimens is generating remissions lasting 3.5 to 4 years, says Raje.
SELECTED
LANGUAGE


Noopur Raje, MD, professor of medicine at Harvard Medical School and director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discusses data for the standard triplet regimens in the treatment of patients with relapsed/refractory multiple myeloma.

The data are promising with regard to the 3-drug combination of carfilzomib (Kyprolis), pomalidomide (Pomalyst), and dexamethasone, Raje says. Response rates are between 60% and 70%, with durations of response of approximately 8 or 9 months.

Moreover, combinations with daratumumab (Darzalex) have also been impressive. The triplet of daratumumab, dexamethasone, and pomalidomide also yields responses in approximately 60% of patients, with durations of response between 8 to 10 months. However, the field is shifting toward the use of quadruplets in this setting, with the goal of achieving minimal residual disease negativity and, ultimately, higher cure rates. Data show that treatment with 4-drug regimens is generating remissions lasting 3.5 to 4 years, says Raje.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x